Category: New products
-
Over-the-Counter Naloxone Receiving Faster FDA Review
The opioid overdose drug naloxone in nasal spray form is receiving priority review from the Food and Drug Administration as an over-the-counter drug.
-
Peptide Discovery Company to Gain $3.3B in Licensing Deals
A discoverer of therapeutic peptides signed licensing deals in the past few days with two drug makers that could bring the company as much as $3.3 billion.
-
Food Protein Biotech Adds €4M in Seed Funds
A new company creating protein ingredients for food products from carbon dioxide converted by engineered bacteria is raising €4 million more in seed funds.
-
Immune Organoid Company Raises $4.3M in Seed Funds
A new company developing 3-D cell and tissue models of lymph nodes for discovery of immunotherapies is raising $4.3 million in seed funds.
-
Personal Allergy Start-Up Gains $16.5M in Early Funds
A new business that provides personalized allergy testing, drug making, and delivery to consumers is raising $16.5 million in its first venture funding round.
-
Trial Shows Gel Clears Common Skin Cancer Wounds
Results of a clinical trial indicate a gel applied to lesions caused by basal cell carcinoma is safe for patients and clears the cancerous skin tumors.
-
Brain-Computer Interface Company Raises $75M in New Funds
A developer of an implanted electronic system that captures and transmits thoughts of movement into signals for digital devices is raising $75 million in venture funds.
-
Trial Testing Ultrasound for Brain Cancer Liquid Biopsies
A clinical trial is underway testing the safety and feasibility of focused ultrasound to enable use of blood tests to monitor a patient’s glioblastoma, a form of brain cancer.
-
New Company Creating High-Capacity Gene Therapies to the Brain
A new business is underway developing gene therapies with higher capacities than most current technologies to treat neurodegenerative disorders.
-
Mental Health VR Companies Merge, Raise $13M
Two developers of virtual reality therapy technology for mental health disorders are combining their operations, and raising $13 million in venture funds.